PTLA - Portola Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.88
+0.99 (+3.82%)
At close: 4:00PM EDT

26.88 0.00 (0.00%)
After hours: 5:32PM EDT

Stock chart is not supported by your current browser
Previous Close25.89
Open25.79
Bid19.39 x 800
Ask28.31 x 800
Day's Range25.79 - 26.98
52 Week Range14.81 - 42.17
Volume702,241
Avg. Volume1,008,783
Market Cap1.831B
Beta (3Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-5.18
Earnings DateAug 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.40
Trade prices are not sourced from all markets
  • Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
    PR Newswireyesterday

    Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

    SOUTH SAN FRANCISCO, Calif. , July 17, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial ...

  • Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors
    PR Newswire10 days ago

    Portola Pharmaceuticals Presents New In Vitro Data Demonstrating that Four-Factor Prothrombin Complex Concentrates (4F-PCCs) Had No Direct Effect on Inhibition of Thrombin Generation by Factor Xa Inhibitors

    SOUTH SAN FRANCISCO, Calif., July 8, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new in vitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and rivaroxaban and the ability of four-factor prothrombin complex concentrate (4F-PCC) to correct inhibition of thrombin generation, compared with warfarin anticoagulation reversal by 4F-PCC. Results showed that, while effective in reversing inhibition of thrombin generation in plasma from patients treated with warfarin, 4F-PCCs did not appear to have an effect on the inhibition of thrombin generation by apixaban or rivaroxaban unless the Factor Xa inhibitor concentration was less than 75 ng/mL.

  • Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
    PR Newswire29 days ago

    Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

    SOUTH SAN FRANCISCO, Calif., June 19, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in patients with relapsed/refractory follicular lymphoma (FL) receiving cerdulatinib alone or in combination with rituximab. Data were presented this month in a poster session at the 24th Congress of the European Hematology Association (EHA) in Amsterdam (June 13-16) and during an oral session today at the 15th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 18-22).

  • Markitlast month

    See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.

    Portola Pharmaceuticals Inc NASDAQ/NGS:PTLAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding PTLA are favorable, with net inflows of $2.34 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire2 months ago

    Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., May 28, 2019 -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,.

  • What’s Portola’s Growth Strategy for Fiscal 2019?
    Market Realist2 months ago

    What’s Portola’s Growth Strategy for Fiscal 2019?

    Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)European market launchOn April 26, Portola Pharmaceuticals (PTLA) issued a press release announcing conditional marketing authorization granted by the European Commission to

  • How Is Portola’s Andexxa Placed in the First Quarter?
    Market Realist2 months ago

    How Is Portola’s Andexxa Placed in the First Quarter?

    Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Reimbursement and accessIn its first quarter earnings conference call, Portola Pharmaceuticals (PTLA) highlighted the stocking of Andexxa by 300 hospitals in the US with a

  • GlobeNewswire2 months ago

    Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous (Non-Traumatic) Intracranial Hemorrhage

    Portola Pharmaceuticals, Inc.® (PTLA) today announced the presentation of a new analysis of data from an important subgroup of  ANNEXA-4, the Company’s Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] in patients with acute major bleeding while taking a Factor Xa inhibitor. Data on a key subset of patients with spontaneous (non-traumatic) intracranial hemorrhage are being featured in an oral presentation today at the 5th European Stroke Organisation Conference (ESOC 2019) in Milan, Italy. Spontaneous intracranial hemorrhage is a bleeding event in the brain not caused by trauma, and it is associated with high rates of mortality and morbidity.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PTLA earnings conference call or presentation 8-May-19 12:30pm GMT

    Q1 2019 Portola Pharmaceuticals Inc Earnings Call

  • 3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results
    Motley Fool2 months ago

    3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results

    The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.

  • Portola Pharmaceuticals Inc (PTLA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Portola Pharmaceuticals Inc (PTLA) Q1 2019 Earnings Call Transcript

    PTLA earnings call for the period ending March 31, 2019.

  • Why Portola Pharmaceuticals Is Tumbling 14.5% Today
    Motley Fool2 months ago

    Why Portola Pharmaceuticals Is Tumbling 14.5% Today

    First-quarter financial results are failing to spark investor optimism on concerns over cash burn.

  • Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Portola Pharmaceuticals (PTLA) Reports Q1 Loss, Tops Revenue Estimates

    Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 0.00% and 6.38%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Portola Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.17. Losses, adjusted for non-recurring costs, came to $1.02 per share. The results matched Wall Street expectations. ...

  • GlobeNewswire2 months ago

    Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

    – First Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya®; Staged Commercial Launch Planned.

  • ACCESSWIRE2 months ago

    Portola Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Portola Pharmaceuticals, Inc. (NASDAQ: PTLA ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 8:30 ...

  • Did Hedge Funds Drop The Ball On Portola Pharmaceuticals Inc (PTLA)?
    Insider Monkey3 months ago

    Did Hedge Funds Drop The Ball On Portola Pharmaceuticals Inc (PTLA)?

    Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost more than 25%. Facebook, which was the second most popular stock, lost 20% amid uncertainty regarding the interest rates and tech […]

  • Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks3 months ago

    Portola Pharmaceuticals (PTLA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that the European Commission (EC) has granted conditional Marketing Authorization for Ondexxya™ (andexanet alfa). Ondexxya is the first and only antidote approved in Europe for adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

  • GlobeNewswire3 months ago

    Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that Dr. John Curnutte, M.D., Ph.D., Executive Vice President and Head of Research and Development, will retire on May 17, 2019, after more than eight years of distinguished service. Dr. Curnutte will remain in a consultancy role, providing guidance to Portola’s President and Chief Executive Officer Scott Garland and engaging with key academic and scientific thoughtleaders in the field on the ongoing development of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] and cerdulatinib.

  • GlobeNewswire3 months ago

    Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019

    Portola Pharmaceuticals, Inc.® (PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended March 31, 2019, and provide a general business overview on Wednesday, May 8, 2019, at 8:30 a.m. ET (5:30 a.m. PT). Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban or apixaban.

  • Portola Pharmaceuticals: Is It Still a Buy?
    Motley Fool3 months ago

    Portola Pharmaceuticals: Is It Still a Buy?

    This commercial-stage company's success depends heavily on the demand for one drug.